Home » Health » Page 195
Category:

Health

Discover the latest in health: evidence‑based wellness tips, medical breakthroughs, nutrition guidance, fitness insights, and expert advice for a healthier, happier life.

Health

Best Fried Fish Tacos at 5 Popular Chain Restaurants

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

The quest for the perfect fish taco is a universal one, and for many, that taco needs to be made now. Fortunately, several chain restaurants are stepping up to the plate, prioritizing fresh ingredients and made-to-order preparation. Forget those sad, pre-fried fillets sitting under a heat lamp – these spots are delivering crispy, flavorful fish tacos that truly satisfy. From Baja-inspired classics to West Coast favorites, here’s where to find some of the best fresh fried fish tacos in the country.

The appeal of a well-executed fish taco is undeniable. It’s a versatile dish, built on a simple foundation of fried fish and a tortilla, but elevated by endless topping possibilities – cabbage, jalapeños, creamy sauces, and fresh avocado are just the beginning. But freshness is key. As one enthusiastic diner put it, “If there are restaurants out there where fish tacos are fried ahead of time and left to sit under a heat lamp, I don’t aim for to realize about them.”

Taco Nazo: An Ensenada-Style Favorite

For consistently fresh and flavorful fish tacos, Taco Nazo consistently receives high marks. Their Ensenada-Style Fish Tacos are reportedly made to order every time, earning rave reviews from customers. “Oh, how I love my fried fish tacos. Crispy, golden batter, soft flaky (non-fishy) fish, fresh toppings, and some good salsa. If that sounds good to you, Taco Nazo is the place to go,” shared one satisfied diner. Taco Nazo has multiple locations, primarily in Southern California, and is a popular choice for those seeking authentic Baja flavors. You can find locations and more information on their website: https://www.taconazo.com/.

Mariscos Jalisco: West Coast Excellence

Mariscos Jalisco, operating primarily as a food truck and with brick-and-mortar locations in California, has garnered a reputation for exceptional freshness. Their motto, “always fresh,” seems to be more than just a slogan. One diner went so far as to say, “Mariscos Jalisco serves, without exaggeration, the best tacos I have ever eaten,” praising the “pure umami” and perfectly balanced flavors. Mariscos Jalisco’s Instagram page showcases their vibrant offerings and commitment to quality ingredients.

Rubio’s Coastal Grill: A Baja-Style Staple

Rubio’s Coastal Grill is perhaps the most well-known chain specializing in Baja-style fish tacos, and they consistently deliver on their promise of freshness. While their lobster taco may not be a standout, according to one customer, their fried and grilled fish tacos are “phenomenal,” complemented by flavorful toppings, sides, and salsas. A diner from the East Coast even stated they’d choose Rubio’s over In-N-Out, highlighting the chain’s unique appeal. Rubio’s Coastal Grill’s website provides location information and menu details.

California Fish Grill: Freshness You Can Taste

California Fish Grill distinguishes itself with a commitment to fresh, flavorful seafood, and their fried fish tacos are no exception. Customers consistently praise the quality of the ingredients and the careful preparation. “Every meal we ordered was fresh, flavorful, and beautifully prepared. You can truly taste the quality of the ingredients,” one customer shared. Another diner discovered a newfound appreciation for corn tortillas after trying them with California Fish Grill’s tacos, noting they were “sooo good.”

Wahoo’s Fish Taco: A Consistent Crowd-Pleaser

Wahoo’s Fish Taco continues to be a reliable source for delicious, made-to-order fried fish tacos. Fans rave about the perfectly seasoned fish, crisp vegetables, and zesty sauces that combine for an “explosion of flavor.” Generous portion sizes and fresh ingredients further contribute to the positive dining experience.

The popularity of fish tacos, rooted in a blend of Mexican and Japanese culinary traditions, continues to grow. Originally influenced by Japanese deep-frying techniques introduced to Ensenada in the early 20th century, the dish has evolved into a beloved staple across the United States. As consumer preferences shift towards fresher, higher-quality ingredients, these chains are responding by prioritizing made-to-order preparation and flavorful combinations.

As the demand for fresh, flavorful food continues to rise, it will be interesting to see how these chains – and others – adapt and innovate their fish taco offerings. The focus on quality ingredients and made-to-order preparation is a positive trend that benefits both diners and the restaurants themselves.

What are your favorite fish taco toppings? Share your thoughts in the comments below!

Disclaimer: The information provided in this article is intended for general knowledge and informational purposes only, and does not constitute medical or dietary advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

0 comments
0 FacebookTwitterPinterestEmail
Health

Paris-Saclay Cancer Cluster: Accelerating French Innovation in Cancer Treatment

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

France is mounting a significant offensive against cancer with a latest initiative designed to drastically shorten the timeline between scientific discovery and patient access to innovative treatments. The Paris-Saclay Cancer Cluster (PSCC), launched in 2022, is poised to receive up to €100 million over the next decade as part of the France 2030 program, coupled with substantial private investment, including a major contribution from Sanofi. This funding aims to transform research into tangible solutions for cancer patients, both adults and children, and establish France as a global leader in oncology.

With over 433,000 new cancer cases diagnosed annually in France, according to the Institut national du cancer, the require for accelerated innovation is critical. While advancements in immunotherapies, targeted therapies, precision medicine, and artificial intelligence have revolutionized cancer care in recent years, a persistent challenge remains: bridging the gap between laboratory breakthroughs and clinical application. The PSCC is designed to address this highly bottleneck.

Located in Villejuif, the PSCC isn’t simply another research center; it functions as an accelerator, bringing together researchers, clinicians, startups, pharmaceutical giants, and cutting-edge technology platforms on a single site. Founding partners include Université Paris-Saclay, Gustave Roussy, the Inserm, the Institut Polytechnique de Paris, and Sanofi, with key additions like Unicancer, the Institut Curie, and the AP-HP. This collaborative model prioritizes working together from the earliest stages of discovery and development, providing support throughout the entire process – from scientific validation and business structuring to securing funding and preparing for early-stage clinical trials.

A Hub for French Oncology

The Paris Saclay Cancer Cluster unites some of France’s leading cancer research centers, notably Gustave Roussy, consistently ranked among the top cancer centers in Europe. The Institut Hospitalo-Universitaire PRISM (IHU PRISM) is as well a key component, focusing on a deeper understanding of the unique biology of each patient’s cancer. It’s a collaborative effort involving CentraleSupélec, Gustave Roussy, the Inserm, Unicancer, and Université Paris-Saclay.

The €100 million investment, part of the broader Biocluster France 2030 program, is intended to build more than just a collection of labs. The goal is to create a dedicated innovation district, complete with shared laboratories, industrial spaces, and shared technological infrastructure. With a total investment of €1.8 billion planned for the campus and 45,000 square meters of operational space expected by 2025, the PSCC aims to reshape the landscape of cancer treatment globally.

Early Results and Focus Areas

Since its inception in 2022, the PSCC has rapidly gained momentum. As of January 2026, the cluster is supporting 77 projects led by biotech and medtech companies, having already backed 110 projects since its creation. These innovations span a wide range of areas, including immunotherapies, biomarkers, medical devices, and the application of artificial intelligence to diagnostics.

The cluster also provides access to eight shared technological platforms, developed in partnership with academic institutions, allowing young companies to utilize state-of-the-art equipment without significant upfront investment. A strategic initiative, PSCC Data, is connecting data from leading centers like the Institut Curie, Gustave Roussy, and Hôpital Foch. Twelve feasibility studies have already been conducted through this portal, which will open to biopharma, medtech, and AI companies in 2026.

Prioritizing Pediatric Cancer Research

The PSCC is placing a particular emphasis on pediatric oncology, recognizing the unique challenges of developing treatments for children’s cancers – lower patient numbers, the need for specialized trials, and the demand for rare expertise. Through initiatives like Hack4Hope, the cluster is mobilizing researchers, clinicians, and industry partners to develop more precise, effective, and patient-centered solutions for young cancer patients.

The Paris-Saclay Cancer Cluster represents a new strategy for France: to turn into a center of excellence in oncology. If this momentum continues, the initial €100 million investment could be a catalyst for even greater advancements, redefining how Europe translates cancer research into concrete solutions for patients.

Disclaimer: This article provides informational content about medical research and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions you may have regarding a medical condition.

What are your thoughts on this new initiative? Share your comments below and support us spread awareness about the latest advancements in cancer research.

0 comments
0 FacebookTwitterPinterestEmail
Health

Newsom Appoints New CA Court of Appeal & Superior Court Judges

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

SACRAMENTO – Governor Gavin Newsom has announced the appointment of three justices to California’s Court of Appeal, alongside seven judges to various Superior Courts across the state. This move comes as part of the governor’s ongoing efforts to fill critical judicial vacancies and enhance the state’s judicial system.

The newly nominated justices include Justice Joanne Motoike, who will serve as Presiding Justice of the Fourth District Court of Appeal, Division Three. Judge Stephen Goorvitch has been appointed as Associate Justice of the Second District Court of Appeal, Division Two, and Judge Amy Guerra will accept on the role of Associate Justice of the Fifth District Court of Appeal. Each of these appointments will require confirmation by the Commission on Judicial Appointments, which includes key figures such as Chief Justice Patricia Guerrero and Attorney General Rob Bonta.

Details of the Appointments

Justice Joanne Motoike, hailing from Orange County, has already served as an Associate Justice in the Fourth District Court since 2022. Her previous roles include a Judge in the Orange County Superior Court and a Senior Deputy Public Defender. Motoike holds a Juris Doctor degree from Loyola Law School and fills a vacancy left by the retirement of Presiding Justice Kathleen E. O’Leary.

Judge Stephen Goorvitch from Los Angeles County has been appointed as an Associate Justice in the Second District Court of Appeal. Goorvitch’s background includes serving as a Judge in the Los Angeles County Superior Court since 2015 and as an Assistant U.S. Attorney. He completed his Juris Doctor degree at the University of California, Berkeley School of Law and takes over the position previously held by Justice Judith T. Ashmann-Gerst.

Lastly, Judge Amy Guerra, from Fresno County, will serve as an Associate Justice in the Fifth District Court of Appeal. Guerra has been a Judge in the Fresno County Superior Court since 2018 and formerly held the position of Chief Defense Attorney at the Fresno County Alternate Defense Office. She holds a Juris Doctor degree from the San Joaquin College of Law and fills the vacancy created by the retirement of Justice Bruce Smith.

Superior Court Judicial Appointments

In addition to the appellate court appointments, Governor Newsom announced the appointment of seven judges to Superior Courts across various counties:

  • Contra Costa County: Carole Bosch, who has served as an Administrative Law Judge since 2021, fills a vacancy left by Judge Patricia Scanlon.
  • Los Angeles County: Victoria Shapiro, previously a Commissioner since 2026, and Anastasia Zykanova, a Deputy Public Defender since 2018, will fill vacancies created by Judge Patrick T. Madden and Judge Ana Luna, respectively.
  • Riverside County: Thanh Ngo, who has worked as a Deputy District Attorney, will fill the position left by Judge Kira K. Klatchko.
  • San Francisco County: Matthew Kahn, a Partner at Gibson Dunn & Crutcher since 2013, fills the vacancy created by Judge Mary E. Wiss.
  • Santa Clara County: Karen Schulz, an Immigration Judge since 2021, and Carl Chamberlin, the Lead Appellate Court Attorney since 1999, will fill vacancies left by Judge Julianne Sylva and Judge Drew Takaichi, respectively.

The compensation for the Court of Appeal justices is $280,052, while the Superior Court judges will receive $244,727.

Implications of the Appointments

The appointments reflect Governor Newsom’s commitment to ensuring that California’s judiciary is staffed with qualified and diverse individuals. With significant experience in public defense, prosecutorial roles, and administrative law, these judges are expected to bring a wealth of knowledge to their respective courts. Their confirmations will be closely watched as they will shape the judicial landscape in California.

Looking ahead, the next step for these justices and judges is to secure confirmation from the Commission on Judicial Appointments. This process is critical in maintaining the integrity of the judicial system and ensuring that the appointed judges can effectively serve the public.

As discussions surrounding judicial appointments continue, the public is encouraged to engage in the process by sharing their thoughts and insights on the importance of judicial diversity and experience in California’s courts.

0 comments
0 FacebookTwitterPinterestEmail
Health

Alzheimer’s: New Blood Test Predicts Onset Timeline & Symptoms

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

A new blood test is offering a potentially groundbreaking way to predict the onset of Alzheimer’s disease, not just whether someone is likely to develop the condition, but when symptoms might begin to appear. Researchers are calling this prediction capability a “clock,” as it estimates the time remaining before cognitive decline manifests. This advancement in early Alzheimer’s diagnosis could dramatically alter how the disease is managed and treated, offering a crucial window for intervention.

For decades, diagnosing Alzheimer’s has relied on identifying symptoms after significant brain damage has already occurred. While tools like PET scans can detect amyloid plaques – a hallmark of the disease – they are expensive, time-consuming, and involve radiation exposure. The new blood test focuses on measuring levels of a specific protein, phosphorylated tau 217 (p-tau217), and the ratio of p-tau217 to beta-amyloid 1-42, offering a less invasive and more accessible diagnostic pathway. The U.S. Food and Drug Administration cleared the first such test in May 2025, marking a significant step forward in Alzheimer’s research and clinical practice.

How the ‘Clock’ Works

The research, published in JAMA Neurology, details how the levels of p-tau217 in the blood correlate with the progression of amyloid pathology in the brain. By analyzing these protein levels, scientists can estimate the number of years until an individual is likely to experience symptomatic Alzheimer’s disease. The test isn’t simply a yes/no answer; it provides a timeline, allowing for more personalized risk assessment and potential treatment strategies. Researchers found that the test can predict the onset of symptoms with a degree of accuracy that was previously unattainable with blood-based biomarkers.

Quest Diagnostics has also added p-tau217 testing to its suite of Alzheimer’s disease diagnostic services, launching the test in April 2024. According to Quest Diagnostics, the test is part of their AD-Detect™ portfolio, which includes other plasma biomarker testing and traditional methods like cerebrospinal fluid analysis and genetic testing.

Implications for Treatment and Research

The ability to predict the timeline of Alzheimer’s onset has profound implications for clinical trials. Currently, many trials enroll patients who already exhibit symptoms, meaning significant brain damage has already occurred. This new blood test allows researchers to identify individuals at high risk of developing the disease *before* symptoms appear, enabling earlier intervention and potentially more effective treatments. The test can be used to monitor the effectiveness of new anti-amyloid therapies, as changes in p-tau217 levels can indicate whether a treatment is slowing disease progression.

Labcorp also offers a p-tau217 plasma test, launched in January 2026. According to Labcorp, a pTau-217 value greater than 0.18 is a surrogate marker for beta amyloid pathology and can be used to facilitate biological identification of Alzheimer’s disease.

Looking Ahead

While the p-tau217 blood test represents a major advancement, it’s vital to remember that it’s not a definitive diagnosis. It’s a tool to be used in conjunction with other clinical evaluations and assessments. Ongoing research is focused on refining the accuracy of the “clock” and identifying other biomarkers that can provide a more comprehensive picture of an individual’s risk. The ultimate goal is to develop effective treatments that can prevent or delay the onset of Alzheimer’s disease, and this new blood test brings us one step closer to that reality.

The development of accessible and accurate diagnostic tools like this blood test is crucial as the prevalence of Alzheimer’s disease is expected to rise significantly in the coming decades. With an aging global population, understanding and addressing this devastating disease is more important than ever. Share your thoughts on this promising development in the comments below.

Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts
@2025 - All Right Reserved.

Hosted by ByoHosting - Most Recommendeed Webhhosting. For complains, abuse, advertising contact:
[email protected]

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.